by Sarah Lazare and Paige Oamek
November 3, 2021
https://inthesetimes.com/article/pfizer ... ty-patents
Extract:
This article was also reprinted by Common Dreams: https://www.commondreams.org/views/2021 ... ct-profits(In These Times) Big Pharma has been caught in a lie that implicates not only major Covid-19 vaccine manufacturers, but also heads of state and members of Congress…
The lie relates to an October 2020 proposal from India and South Africa that the World Trade Organization suspend enforcement of key patent rules so that cheaper, generic versions of Covid-19 treatments and vaccines can get to more people more quickly…The pharmaceutical giants Pfizer and Moderna, …emerged as virulent opponents of such a measure, which still has not passed more than a year later, even as just one out of 21 people in poor countries have been fully vaccinated. It is no anomaly that the industry would reject such a proposal—pharmaceutical companies had a big hand in shaping those WTO intellectual property rules in the first place, to protect pharmaceutical monopolies and their profits.
But in order to protect strict intellectual property rules while also protecting its public image, the pharmaceutical industry had to weave a narrative that portrays companies as driven by altruistic motives: the desire to protect innovation and research, and ensure safe and responsible vaccine production. Among talking points about how intellectual property incentivizes creativity, and rewards those who save lives, a key argument has emerged: Sharing vaccine recipes is not the panacea you think it is, because much of the world—i.e. the Global South—lacks the facilities and capacity to produce vaccines in a safe and timely manner. Even if we got rid of all intellectual property rules tomorrow, this would do little to boost immediate global vaccine supply.
…
But, it turns out, empirical claims can be empirically disproven. On October 22, the New York Times ran a story titled, "Here's Why Developing Countries Can Make mRNA Covid Vaccines" that identifies 10 different facilities in India, Brazil, Thailand, South Africa, Argentina and Indonesia that are strong candidates for producing mRNA vaccines. "The key criteria include existing facilities, human capital, the regulatory system for medicines and the political and economic climate," writes journalist Stephanie Nolen. Some of the facilities are already producing other vaccines, or testing or making their own mRNA vaccines. In other words, Global South countries could absolutely start producing Pfizer and Moderna vaccines, if the companies would only tell them how.
